Premier Alternatives

OncoResponse

Houston, TX · Founded 2015 · Privately Held (backing)

Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of patients who have responded exceptionally well to checkpoint inhibition. OncoResponse is based in Houston, TX and was founded in 2015. Its last reported valuation was $36 million in May 2023. It has raised $180 million across 2 recorded rounds; the latest was a $6 million early-stage round in Apr 2025.

Last reported valuation
$36.0M
Oct 2026
Priced at
—
Total raised
$180.0M
Last round
Early Stage VC
Apr 2025

OncoResponse key facts

as of Oct 2026
  • Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of patients who have responded exceptionally well to checkpoint inhibition.
  • OncoResponse is valued at approximately $36.0M as of Oct 2026 (last reported valuation).
  • It has raised $180.0M across 2 recorded rounds; the latest was Early Stage VC ($6.0M) in Apr 2025.
  • Notable investors include Alexandria Venture Investments, Canaan Partners, InterVest, ARCH Venture Partners, Qatar Investment Authority — 25 tracked in total.
  • OncoResponse has filed 2 Form Ds with the SEC since 2018, most recently May 2025 ($6.0M sold to 9 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$36.0M

OncoResponse's last reported valuation, May 2023. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of OncoResponse with a free account
  • ·The complete investor list: 25 names
  • ·Watch OncoResponse: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

OncoResponse funding rounds

2 rounds
Apr 2025Early Stage VC$6.0MSEC filing▮
Aug 2018Early Stage VC$19.0MSEC filing▮
Full funding history →

OncoResponse valuation

OncoResponse's last reported valuation was $36 million in May 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has OncoResponse raised?

OncoResponse has raised $180 million in total; 2 of its rounds are on record. The largest on record was a $6 million early-stage round in Apr 2025.

OncoResponse has filed 2 Form Ds with the SEC since 2018, most recently in May 2025 ($6 million sold to 9 investors).

OncoResponse investors

25 investors are on record for OncoResponse, including Alexandria Venture Investments, Canaan Partners, InterVest and ARCH Venture Partners. By type, the record holds 5 venture capital firms and 2 family offices. The early-stage round in Apr 2025 drew 9 investors.

About OncoResponse

Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of patients who have responded exceptionally well to checkpoint inhibition. The company leverages a proprietary B-cell technology platform to develop cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system, helping doctors and patients to combat cancer optimally.

Sector
Healthcare
HQ
Houston, TX, United States
Founded
2015
Employees
11
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.